ARNA Financial Facts

Other: 477K
Net loss per share allocable to common stockholders, basic: -0.13
See Full Income Statement

Accounts receivable: 4.93M
Current portion of derivative liabilities: -2.88M
See Full Balance Sheet

Arena Pharmaceuticals, Inc. (ARNA) Earnings

  |   Expand Research on ARNA
Next EPS Date 5/10/16 *Est. EPS Growth Rate +13.3% *Last Qtr.
Average EPS % Beat Rate +16.3% Revenue Growth Rate -15.2% *Last Qtr.
Average % Move 1-Wk after EPS -3.3% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
2/29/16 Q415 -$0.13-$0.13 $0.00$7.8M$8.26M N/A Details
11/10/15 Q315 -$0.11-$0.13 +$0.02$9.1M$9.14M N/A Details
8/5/15 Q215 -$0.11-$0.14 +$0.03$9.18M$10.95M N/A Details
5/11/15 Q115 -$0.10-$0.14 +$0.04$12.3M$10.56M N/A Details
3/2/15 Q414 -$0.15-$0.12 -$0.03$9.2M$10.36M N/A Details
11/3/14 Q314 -$0.05-$0.12 +$0.07$8.2M$10.9M N/A Details
8/1/14 Q214 $0.03-$0.11 +$0.14$12.8M$9.81M N/A Details
5/12/14 Q114 -$0.12-$0.10 -$0.02$6.8M$7.98M N/A Details